12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

JVS-100: Phase IIa started

Juventas began the double-blind, placebo-controlled, dose-escalation, international Phase IIa STOP-CLI trial to evaluate intramuscular injections of JVS-100 in about 48 patients with Rutherford Class 4-5 CLI. Patients will receive 8...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >